Sponsor or institution
Clinical trials and research at Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
As of November 12, 2026, Find a Trial lists 71 clinical trials run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. that are recruiting, in China. By phase: Phase 1 (19), Phase 2 (17), Phase 3 (16), Phase 1/2 (14). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 71Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| TQF3250 Capsules in overweight and obese adults with limited weight loss from lifestyle changes | Phase 1 | Beijing, Beijing Municipality and 9 other locations | Recruiting | Sep 1, 2026 |
| TQF3250 capsules for adults with type 2 diabetes and overweight/obesity | Phase 1 | Fuzhou, Fujian and 11 other locations | Recruiting | Aug 5, 2026 |
| GPC3-targeted ADC for advanced solid tumors | Phase 1 | Hefei, Anhui and 7 other locations | Recruiting | Jul 28, 2026 |
| TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis | Phase 3 | Beijing, Beijing Municipality and 44 other locations | Recruiting | Jul 24, 2026 |
| TQB3126 in Breast Cancer: Safety, PK, and Early Efficacy in Adults | Phase 1/2 | Guangzhou, Guangdong and 5 other locations | Recruiting | Jul 13, 2026 |
| Tabellvi for moderate to severe Crohn's disease in Chinese adults | Phase 4 | Fuyang, Anhui and 6 other locations | Recruiting | Jun 23, 2026 |
| Adalimumab treatment for adults with non-infectious uveitis | Phase 4 | Tianjin, Tianjin Municipality | Recruiting | Jun 23, 2026 |
| TQB2930 plus chemo with or without bevacizumab for HER2-abnormally expressed advanced colorectal cancer | Phase 1/2 | Beijing, Beijing Municipality and 30 other locations | Recruiting | Jun 17, 2026 |
| Adalimumab in Children with Crohn’s Disease (Pediatric 6–17) | Phase 4 | Guangzhou, Guangdong | Recruiting | May 4, 2026 |
| TQ05105 tablets for intermediate/high-risk myelofibrosis | Phase 2 | Hefei, Anhui and 23 other locations | Recruiting | Apr 24, 2026 |
All recruiting trials (71)
-
TQF3250 Capsules in overweight and obese adults with limited weight loss from lifestyle changes
This phase 1b study tests whether TQF3250 capsules are safe and tolerable, and whether they show preliminary signs of benefit, in adults with overweight or obesity who have not achieved enough weight loss with simple lifestyle changes.
-
TQF3250 capsules for adults with type 2 diabetes and overweight/obesity
A small, early-phase study will test the safety and how the body handles different doses of TQF3250 pills in adults with type 2 diabetes who are overweight or obese.
-
GPC3-targeted ADC for advanced solid tumors
This early-phase trial tests a Glypican-3 targeted antibody-drug conjugate (TQB6426) in adults with advanced cancers to see if it is safe and tolerable and to explore potential anti-tumor activity.
-
TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis
This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.
-
TQB3126 in Breast Cancer: Safety, PK, and Early Efficacy in Adults
This study tests TQB3126 to see if it is safe and tolerable and to get early signals of benefit in adults with breast cancer who have progressed after prior therapy.
-
Tabellvi for moderate to severe Crohn's disease in Chinese adults
This real-world, single-arm study tests Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease to see how often side effects occur and whether many patients reach remission by week 26.
-
Adalimumab treatment for adults with non-infectious uveitis
This trial tests whether TyboWe Adalimumab can help adults with non-infectious uveitis who are already on steroids.
-
TQB2930 plus chemo with or without bevacizumab for HER2-abnormally expressed advanced colorectal cancer
This trial tests a drug called TQB2930 together with standard chemotherapy, with or without bevacizumab, in adults whose colorectal cancer cannot be removed by surgery and shows HER2 abnormal expression.
-
Adalimumab in Children with Crohn’s Disease (Pediatric 6–17)
This study tests Taibowei Adalimumab injections in children aged 6 to 17 who have moderately to severely active Crohn’s disease to see how safe it is over 12, 26, and 52 weeks.
-
TQ05105 tablets for intermediate/high-risk myelofibrosis
This phase 2 study tests TQ05105 tablets to see if they help people with intermediate or high-risk myelofibrosis who have not benefited from prior JAK inhibitors.
-
Benmelstobart plus anlotinib for advanced or inoperable alveolar soft part sarcoma
This trial will test whether combining benmelstobart injections with anlotinib pills helps people aged 14 and older who have advanced or unresectable alveolar soft part sarcoma.
-
Polymyxin E2 Therapy for Carbapenem-Resistant Hospital- or Ventilator-Associated Pneumonia
This study tests a Polymyxin E2 medicine given as an injection to adults with hospital-acquired or ventilator-associated pneumonia caused by carbapenem-resistant bacteria to see if it is safe and helps recovery.
-
Targeted combo therapy for HER2-expressing advanced solid tumors
This trial tests whether giving TQB2930 with TQB2102 can help people with HER2-expressing advanced solid tumors.
-
TQH3906 in Systemic Lupus Erythematosus (Phase 2)
This study tests whether TQH3906 capsules are safe and helpful for people with systemic lupus erythematosus.
-
TQB3205 capsules for adults with advanced malignant tumors.
TQB3205 capsules will be tested for safety, tolerability, and how the drug is processed in the body in adults with advanced malignant tumors.
-
How a single dose of TQ05105 is processed and tolerated in people with liver impairment
This study will give one dose of the medicine TQ05105 to adults with myelofibrosis who have different levels of liver impairment to see how the drug is handled by the body and whether it is safe.
-
Inhaled TQC3721 Suspension for COPD: a Phase 3 trial
A Phase 3 trial tests inhaled TQC3721 suspension in adults with moderate-to-severe COPD to see if it is safe when used over time.
-
TQ-B3234 capsules for adults with symptomatic, inoperable NF1 plexiform neurofibromas
This study will see if oral TQ-B3234 capsules can shrink or reduce symptoms from inoperable plexiform neurofibromas in adults with neurofibromatosis type 1 by Week 24 compared with placebo.
-
TQH3906 capsules for active psoriatic arthritis in adults
This trial tests whether TQH3906 capsules help people with active psoriatic arthritis more than a placebo over 12 weeks.
-
TQH2722 injection plus regular allergy treatment for seasonal pollen allergy
This trial will test whether adding TQH2722 injections to usual care helps adults (18–75) with seasonal allergic rhinitis who had poor symptom control during pollen season.
-
LM-302 with tislelizumab plus chemotherapy for stomach and gastroesophageal junction cancer
This phase 3 study tests whether LM-302 added to tislelizumab is better or safer than tislelizumab with chemotherapy in patients with newly diagnosed, unresectable or metastatic stomach/GEJ adenocarcinoma that express CLDN18.2.
-
TQB6411 injection for advanced lung cancer.
This trial will test whether TQB6411 injection is safe and can help people with advanced lung cancer.
-
TQB6411 injection for recurrent or metastatic esophageal cancer after PD‑1/PD‑L1 and platinum chemotherapy
This trial will try TQB6411 injections in people with recurrent or metastatic esophageal cancer whose disease progressed after PD‑1/PD‑L1 immunotherapy plus platinum chemotherapy to see if it is safe and helps control the cancer.
-
See if TQB3142 is tolerated and how it behaves in people with advanced cancers
This early-phase test checks whether TQB3142 injections are safe to use and how the drug moves through the body in adults with advanced tumors.
-
TQF3250 capsules in healthy adults
Test TQF3250 capsules, a biased GLP-1 receptor agonist, in healthy Chinese adults to see how the drug behaves in the body and whether it is safe and well tolerated.
-
Testing TQB3122 capsules in adults with advanced solid tumors
This trial will try TQB3122 capsules in adults with advanced solid tumors who have exhausted standard treatments to check safety, how the body handles the drug, and any early signs it might work.
-
TQB2934 injection for systemic light chain amyloidosis
This trial will test whether a subcutaneous injection of TQB2934 is safe and can improve blood response in adults with relapsed or refractory systemic light chain amyloidosis who have had daratumumab and bortezomib.
-
TQB2922 subcutaneous treatment for advanced cancers
This Phase I test will try a new injectable drug, TQB2922, to see if it's safe and how the body handles it in adults with advanced non-squamous non-small cell lung cancer.
-
Subcutaneous TQB2934 injection for adults with multiple myeloma
This will test a subcutaneous bispecific antibody, TQB2934, that links patients' T cells to BCMA-positive myeloma cells in adults with relapsed or refractory multiple myeloma.
-
TQB2868 plus anlotinib with chemotherapy versus placebo plus chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma
This trial will see if adding TQB2868 injection and anlotinib capsules to first-line chemotherapy helps adults with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer than chemotherapy with placebo.
-
TQB2101 for adults with advanced blood cancers
This trial will test whether TQB2101, an antibody‑drug conjugate that targets ROR1, is safe and can shrink tumors in adults with advanced hematologic malignancies who have no effective standard treatment options.
-
TQB2930 plus chemotherapy for HER2-positive advanced breast cancer
This study tests whether TQB2930 with chemotherapy works better than trastuzumab with chemotherapy for people with HER2-positive advanced breast cancer who have already had at least two anti-HER2 treatments.
-
TQB2922 with TAS-102, with or without bevacizumab, for chemo‑resistant RAS/BRAF wild‑type advanced colorectal cancer
This study will test whether adding the experimental drug TQB2922 to TAS‑102, with or without bevacizumab, helps people with RAS/BRAF wild‑type advanced colorectal cancer that has stopped responding to standard chemotherapy.
-
TQB6411 injection for advanced EGFR/c‑Met–expressing solid tumors
This phase 1 trial tests TQB6411, an antibody–drug that targets EGFR and c‑Met, to try to kill tumor cells in adults with advanced solid tumors who have exhausted standard treatments.
-
Neoadjuvant TQB2102 versus TCbHP for HER2-positive breast cancer
This study will test whether TQB2102 given before surgery helps people with HER2-positive breast cancer as much as or better than the standard TCbHP treatment.
-
TQB3909 tablets combined with azacitidine for myeloid malignancies
This trial tests whether taking oral TQB3909 together with azacitidine helps adults with myeloid malignancies respond better to treatment and tolerate therapy.
-
TQB2102 injection versus trastuzumab emtansine for HER2-positive advanced breast cancer
This trial tests whether TQB2102 injection works as well as trastuzumab emtansine for adults with HER2-positive unresectable or metastatic breast cancer.
-
TQB2102 versus docetaxel with trastuzumab and pertuzumab for HER2-positive recurrent or metastatic breast cancer
This trial will test whether TQB2102 works as well as docetaxel plus trastuzumab and pertuzumab for adults with HER2-positive recurrent or metastatic breast cancer.
-
First-line treatment for metastatic pancreatic cancer using TQB2916 with chemotherapy
This study is testing a new treatment combining TQB2916 with chemotherapy to see if it helps people with metastatic pancreatic cancer feel better and live longer.
-
TQB3019 capsules for adults with advanced malignant tumors — safety and early effects
This phase 1 trial will test whether TQB3019 capsules are safe and show early signs of benefit in adults with advanced malignant tumors.
-
TQB3473 tablets for treating adult primary immune thrombocytopenia
This study is testing if TQB3473 tablets can help adults with chronic immune thrombocytopenia who haven't responded well to standard treatments feel better and have more stable blood platelet levels.
-
Treatment of advanced thyroid cancer with AL2846 capsules
This study is testing if AL2846 capsules can help people with advanced thyroid cancer that hasn't responded to other treatments live longer without their cancer getting worse.
-
Combining TQB2825 Injection with Chemotherapy for Diffuse Large B-cell Lymphoma
This study is testing if adding a new injection called TQB2825 to standard chemotherapy can help adults with diffuse large B-cell lymphoma feel better and improve their treatment results.
-
Treatment for severe asthma using TQC2731 injection
This study is testing if an injection called TQC2731 can help adults with severe asthma who aren't getting enough control from their current treatments.
-
Treatment for Diffuse Large B Cell Lymphoma using TQB2825 Injection and Immunochemotherapy
This study is testing a new injection called TQB2825 combined with standard treatments to see if it helps people with untreated or returning diffuse large B-cell lymphoma feel better and live longer.
-
Treatment for advanced solid tumors using LM-108 and other therapies
This study is testing a new treatment called LM-108 combined with other cancer therapies to see if it helps people with advanced solid tumors feel better.
-
LM-108 with penpulimab plus albumin-bound paclitaxel and gemcitabine for advanced pancreatic cancer (Cohort C)
This study will test whether adding LM-108 to penpulimab with albumin-bound paclitaxel and gemcitabine helps people with advanced pancreatic cancer.
-
Treatment of advanced gynecological tumors with TQB2102 injection
This study is testing a new injection called TQB2102 to see if it can help people with advanced gynecological tumors feel better while causing fewer side effects.
-
Combining TQB2868 injection, Anlotinib, and chemotherapy for treating metastatic pancreatic cancer
This study is testing a new combination of TQB2868 injection, Anlotinib, and chemotherapy to see if it can help people with metastatic pancreatic cancer feel better and live longer.
-
TQB2102 with immune therapy, with or without chemotherapy, for HER2‑positive advanced gastroesophageal cancer
This test will see if TQB2102, a new HER2‑targeting antibody‑drug conjugate given with benmelstobart and sometimes the PD‑1 antibody penpulimab and chemotherapy, can improve responses in people with unresectable, recurrent, or metastatic HER2‑positive gastroesophageal adenocarcinoma.
-
TQH3906 capsules for adults with moderate-to-severe ulcerative colitis or Crohn's disease
This trial will test whether taking TQH3906 capsules helps adults with moderate-to-severe ulcerative colitis or Crohn's disease control their symptoms over a 12-week treatment period.
-
Evaluating TQB2029 injection for treating multiple myeloma
This study is testing a new injection called TQB2029 to see how safe it is and if it can help adults with multiple myeloma.
-
Comparing Rovadicitinib to Other Treatments for Chronic Graft-versus-host Disease
This study is testing if Rovadicitinib can help people with moderate to severe chronic graft-versus-host disease who haven't found relief from other treatments.
-
Testing TQB3002 in patients with advanced cancers
This study is testing a new pill called TQB3002 to see if it can help people with advanced cancers that haven't responded to other treatments.
-
Evaluating a new treatment for Non-alcoholic Steatohepatitis
This study is testing a new treatment for Non-alcoholic Steatohepatitis (NASH) to see if it can improve liver health in adults.
-
Evaluating TQB3702 tablets with immunochemotherapy for B-cell lymphoma treatment
This study is testing if TQB3702 tablets can work better with immunochemotherapy to help people with relapsed or hard-to-treat B-cell lymphoma.
-
Evaluating TQB3455 Tablets for Patients with Blood Cancers
This study is testing a new tablet called TQB3455 to see if it is safe and effective for people with blood cancers like acute myeloid leukemia and myelodysplastic syndrome.
-
Treatment for Non-small Cell Lung Cancer with HER2 Gene Abnormality
This study is testing a new treatment called TQB2102 for people with advanced lung cancer that has a HER2 gene issue, to see if it helps when standard treatments haven't worked.
-
Evaluating TQB2102 for HER2 negative breast cancer treatment
This study is testing a new injectable treatment called TQB2102 for people with HER2 negative breast cancer that has come back or spread, to see if it can help them when other treatments have not worked.
-
Treatment of HER2-positive Biliary Tract Cancer with TQB2102
This study is testing a new injection called TQB2102 to see if it can help people with advanced HER2-positive biliary tract cancer who haven't had success with other treatments.
-
Testing TQB3107 tablets in patients with advanced cancers
This study is testing TQB3107 tablets to see if they are safe and effective for people with advanced cancers.
-
Using Angiotensin II to treat refractory distributed shock
This study is testing if an injection of angiotensin II can help people with severe shock who haven't improved with regular treatments.
-
Treatment of chronic graft-versus-host disease with TQ05105 tablets
This study is testing if TQ05105 tablets can help improve symptoms and overall health in adults with moderate-to-severe chronic graft-versus-host disease after a stem cell transplant.
-
Comparing D-1553 Tablet to Docetaxel Injection for Advanced Lung Cancer
This study is testing if a new tablet called D-1553 works better than the standard Docetaxel injection for patients with advanced lung cancer who have a specific genetic mutation and haven't had success with other treatments.
-
Treatment with TQB2930 for advanced breast cancer
This study is testing a new treatment called TQB2930 for people with advanced breast cancer to see if it is safe and effective, both on its own and when combined with other chemotherapy drugs.
-
Evaluating TQB2922 injection for patients with advanced cancers
This study is testing a new injectable treatment called TQB2922 to see if it can help adults with advanced cancers who have run out of other options.
-
Treatment of Myelofibrosis with TQ05105 and TQB3617
This study is testing a new combination of TQ05105 tablets and TQB3617 capsules to see if it can help people with intermediate- and high-risk Myelofibrosis feel better.
-
Using Anlotinib capsules to treat advanced thyroid cancer
This study is testing if Anlotinib capsules can help people with advanced thyroid cancer that doesn't respond to standard treatments feel better and have fewer side effects.
-
Combining TQB2450 with chemotherapy or anlotinib for treating non-small cell lung cancer
This study is testing if adding a new drug called TQB2450 to chemotherapy or another treatment can help people with non-small cell lung cancer do better after surgery.
-
Combining Anlotinib and Penpulimab for Hepatocellular Carcinoma Treatment
This study is testing if a new combination of two treatments can help prevent liver cancer from coming back in patients who are at high risk after surgery or other treatments.
-
Evaluating Anlotinib for Advanced Medullary Thyroid Cancer
This study is testing whether Anlotinib can help people with advanced medullary thyroid cancer feel better and manage their disease more effectively.
Quick answers
How many clinical trials run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. are recruiting right now?
71, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 19, Phase 2: 17, Phase 3: 16, Phase 1/2: 14. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.